The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Esperion Therapeutics Inc shares valued at $106 were sold by Warren Eric on Apr 17 ’25. At $0.98 per share, Warren Eric sold 108 shares. The insider’s holdings dropped to 370,218 shares worth approximately $0.3 million following the completion of this transaction.
Also, Halladay Benjamin sold 8 shares, netting a total of over 8 in proceeds. Following the sale of shares at $0.96 each, the insider now holds 481,702 shares.
Before that, Halladay Benjamin had added 8 shares to its account. In a trade valued at $8, the Officer bought Esperion Therapeutics Inc shares for $0.96 each.
As published in their initiating research note from Goldman on December 18, 2024, Esperion Therapeutics Inc [ESPR] has been a Neutral and the price target has been revised to $4. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of June 20, 2024, BofA Securities has decreased its “Neutral” rating to a “an Underperform” for ESPR. Earlier on January 03, 2024, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for ESPR stock which previously was a “a Buy”.
Analyzing ESPR Stock Performance
During the last five days, there has been a surge of approximately 3.32%. Over the course of the year, Esperion Therapeutics Inc shares have dropped approximately -63.50%. Shares of the company reached a 52-week high of $2.4000 on 01/14/25 and a 52-week low of $0.6925 on 05/15/25.
Support And Resistance Levels for Esperion Therapeutics Inc (ESPR)
According to the 24-hour chart, there is a support level at 0.7787, which, if violated, would cause prices to drop to 0.7543. In the upper region, resistance lies at 0.8487. The next price resistance is at 0.8943. RSI (Relative Strength Index) is 39.27 on the 14-day chart, showing neutral technical sentiment.
